1 Min Read
April 27 (Reuters) - Gilead Sciences Inc:
* EUROPEAN CHMP ADOPTS POSITIVE OPINION FOR GILEAD’S BIKTARVY® (BICTEGRAVIR, EMTRICITABINE, TENOFOVIR ALAFENAMIDE) Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.